Superoxide dismutase for therapeutic use: Clinical experience, dead ends and hopes

Molecular and Cellular Biochemistry

Volumn 84, Issue 2, 1988, Pages 123-131

  Flohé, Leopold ^a  

^a GRÜNENTHAL GMBH   (Germany)

Author keywords

clinical trials; inflammation; rec human superoxide dismutase; superoxide dismutase

Indexed keywords

RECOMBINANT PROTEIN; SUPEROXIDE DISMUTASE;

ALLERGIC REACTION; ARTHRITIS; CATTLE; GENETIC ENGINEERING; HUMAN; INTERSTITIAL CYSTITIS; INTRAARTICULAR DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; OSTEOARTHRITIS; PEYRONIE DISEASE; RADIATION CYSTITIS; REVIEW; RHEUMATOID ARTHRITIS;

ANIMAL; CATTLE; HUMAN; SUPEROXIDE DISMUTASE;

EID: 0024208130     PISSN: 03008177     EISSN: 15734919     Source Type: Journal    
DOI: 10.1007/BF00421046     Document Type: Article

References (73)

1. Superoxide Dismutases: Protein chemistry and structure function relationships
2. Die unerwunschte Sauerstoffaktivierung dokumentiert am Beispiel bestimmter Entzündungen: der Weg zur Anwendung der Superoxiddismutase
3. Orgotein, the drug version of bovine Cu/Zn superoxide dismutase: I. A summary account of safety and pharmacology in laboratory animals
4. Superoxide dismutase: an enzymatic function for erythrocuprein (hemocuprein)
5. Orgotein: a new antiinflammatory metalloprotein drug: preliminary evaluation of clinical efficacy and safety in degenerative joint disease
6. Orgotein, the drug version of bovine Cu/Zn superoxide dismutase: II. A summary account of clinical trials in man and animals
7. Biological defense mechanisms. The production by leukocytes of superoxide, a potential bactericidal agent
8. Superoxide production by rabbit alveolar macrophages
9. Oxygen-centered free radicals as mediators of inflammation
10. Generation of superoxide dismutase anion and chemiluminescence by human monocytes during phagocytosis and on contact with surface-bound immunoglobulin G
11. Oxidative stress in human neutrophilic granulocytes: host defence and self-defence
12. Complement and immunoglobulins stimulate superoxide production by human leukocytes independently of phagocytosis
13. Comparative studies on superoxide anion production by polymorphonuclear leukocytes stimulated with various agents
14. Chemotactic factor-induced generation of superoxide radicals by human neutrophils: effect of metabolic inhibitors and antiinflammatory drugs
15. Is Leukotriene B4-induced chemotaxis mediated by superoxide?
16. Platelet activating factor (PAF) induces the oxidative burst in macrophages
17. Inhibition of lipid peroxidation in isolated inner membrane of rat liver mitochondria by superoxide dismutase
18. Oxidation of glutathione by the superoxide radical to the disulfide and the sulfonate yielding singlet oxygen
19. Free radicals and inflammation: protection of synovial fluid by superoxide dismutase
20. Hyaluronic acid degradation by reactions producing activated oxygen species
21. Effect of oxygen-derived free radicals on connective tissue macromolecules
22. Effects of oxygen radicals, PAF-acether and leukotrienes on collagen metabolism
23. In vitro suppression of serum elestase-inhibitory capacity by reactive oxygen species generated by phagocytosing polymorphonuclear leukocytes
24. A role for superoxide in granulocyte mediated inflammation
25. Some immunological consequences of free radical production in rheumatoid arthritis
26. A role for superoxide in granulocyte mediated inflammation
27. Free radical scavengers as antiinflammatory drugs?
28. Effectiveness of superoxide dismutase in osteoarthritis of the knee joint. Results of a double blind multicenter clinical trial
29. Ergebnis einer multizentrischen Orgotein-Prüfung bei Gonarthrose
30. Orgotein in osteoarthritis of the knee joint
31. Intra-articular orgotein-therapy in osteoarthritis of the knee. A doubleblind, placebo-controlled trial
32. Clinical comparison of orgotein and methylprednisolone acetate in the treatment of osteoarthrosis of the knee joint
33. Therapeutic benefits of oxygen radical scavenger treatments remain unproven
34. 10 Jahre therapeutische Erfahrungen mit Superoxid-Dismutase
35. Double-blind controlled clinical trials in man with bovine copper-zinc superoxide dismutase (Orgotein)
36. Superoxyde dismutase et polyarthrite rhumatoide
37. Intrasynovialorgotein-therapy in rheumatoid arthritis
38. Effect of intraarticular orgotein versus a corticosteroid on rheumatoid arthritis of the knees
39. Über die Behandlung der Epicondylitis mit lokal injiziertem Orgotein (Doppelblindstudie)
40. Studio comparativo in dopio cieco cross-over tra orgoteina e metilprednisolone
41. Orgotein: a new antiinflammatory metalloprotein drug evaluation of clinical efficacy and safety in inflammatory conditions of the urinary tract
42. Orgotein: a new drug for the treatment of radiation cystitis
43. Orgotein: a new drug for the treatment of radiation cystitis
44. Klinische Erfahrungen mit Orgotein bei urologischen Erkrankungen
45. Ergebnisse einer multizentrischen Orgoteinprüfung bei Strahlen- und interstitiellen Cystitiden
46. Die Behandlung der Schrumpfharnblasen mit Orgotein
47. Behandlung des Ulcus simplex vesicae und der ulcerierenden radiogenen Cystitis mit Superoxiddismutase
48. Superoxiddismutase (SOD): Erste Erfahrungen bei der Anwendung eines neuen anti-inflammatorischen Prinzips in der Behandlung der ulzerierenden Zystitis und der Induratio penis plastica (IPP)
49. Subclinical peyronie's disease
50. Surgery of the penis and urethra
51. Induratio penis plastica (IPP), pathomorphologische Gesichtspunkte
52. Erfahrungen bei der Behandling der Induratio penis plastica mit Orgotein und ihre Sicherheit
53. Orgotein efficacy in ameliorating side effects due to radiation therapy. I. doubleblind, placebo-controlled trial in patients with bladder tumors
54. Orgotein efficacy in ameliorating side effects due to radiation therapy
55. Superoxide dismutase efficacy in ameliorating side effects of radiation therapy: double-blind, placebocontrolled trials in patients with bladder and prostate tumors
56. LOrgoteina nella prevenzione della mucosite da raggi a livello oro-faringeo
57. Oxygen radicals: Physiological and medical aspects, with specific reference to high energy irradition
58. Ten years of clinical experience with SOD treatment in inflammatory disorders
59. Superoxide Dismutase: rationale for use in reperfusion injury and inflammation
60. Free-radical-mediated postischemic reperfusion injury in the kidney
61. Leukotriene D4 mediates galactosamine/endotoxin-induced hepatitis in mice
62. Lung injury secondary to chemotactic factor-induced leukocyte activation
63. Oxygen radical dependent lung damage following thermal injury of rat skin
64. Nucleotide sequence and expression of human chromosome 21-encoded superoxide dismutase mRNA
65. Human Cu/Zn superoxide dismutase cDNA: Isolation of clones synthesising high levels of active or inactive enzyme from an expression library
66. Comparison of human Cu/Zn superoxide dismutase derived from erythrocytes, recombinant E. coli and recombinant yeast
67. Comparison of the protective effects by human and bovine superoxide dismutase against ischemia and reperfusion induced impairment of kidney function in anesthetized rats
68. Enhanced myocardial salvage by combined treatment with recombinant single-chain urokinase-type plasminogen activator and recombinant human superoxide dismutase in a canine coronary thrombosis model